Government mail service may be affected by the Canada Post labour disruption. Learn about how critical government mail will be handled.
Measles cases in Alberta
Measles transmission is currently occurring in Alberta, affecting individuals of all ages – including infants, children and adults. Most reported cases have been in children under 5 years old and those aged 5 to 17 who are not immunized.
Cases have been reported in all zones of the province, with the highest numbers in the north, south and central zones. Due to the number of people in these areas who may not be immune to measles, it’s likely that some cases are going undetected or unreported.
Alberta Health Services shares known public exposure locations for the Edmonton, Calgary, Central and parts of the North Zone. A standing exposure advisory has been issued for the South Zone, North Zone and Parkland County including communities of Spruce Grove and Stony Plain. Site-specific exposure advisories will no longer be issued in these locations.
All Alberta residents, workers, students and visitors are advised to be aware of the increased risk of measles and ensure their measles immunizations are up to date.
Table 1. Confirmed measles cases reported in 2026 by zone as of 12 pm, February 25, 2026
| Geography | Cases since last update | Total cases reported in 2026 | Cases no longer communicable* | Cases currently known to be communicable (active)** |
|---|---|---|---|---|
| North Zone | 26 | 26 | 0 | |
| Edmonton Zone | 14 | 12 | 2 | |
| Central Zone | 1 | 13 | 12 | 1 |
| Calgary Zone | 0 | 0 | 0 | |
| South Zone | 2 | 35 | 34 | 1 |
| Alberta | 3 | 88 | 84 | 4 |
Data note(s):
- The 'total' number of cases referenced here refers to confirmed cases only.
- *Period of communicability – the time the other person can transmit measles to another person.
- Public health will determine period of communicability for individual measles cases for the purposes of contact management.
- **Active cases does not reflect risk in the community as there may be people with undiagnosed measles, nor does it reflect the number of persons who have been exposed to measles. This estimated number is used for public reporting purposes only.
Table 2. Confirmed measles cases currently hospitalized February 24, 2026
| Currently hospitalized | Cases |
|---|---|
| Non-ICU | 1 |
| ICU | 1 |
| Total | 2 |
Data note(s):
- Currently hospitalized data are provided by Alberta Health Services. This data does not include cases reported to Alberta Primary and Preventative Health Services from Indigenous Services Canada.
- People in hospital who are not yet diagnosed or reported as a confirmed measles case are not included.
Weekly reporting
Table 3. Confirmed measles cases by zone and year
| Geography | 2025 | 2026 |
|---|---|---|
| North Zone | 761 | 24 |
| Edmonton Zone | 44 | 3 |
| Central Zone | 137 | 12 |
| Calgary Zone | 52 | 0 |
| South Zone | 1,014 | 27 |
| Alberta | 2,008 | 66 |
Table 4. Confirmed measles cases by age group and year
| Age group | 2025 | 2026 |
|---|---|---|
| <5 years | 581 | 19 |
| 5 to 17 years | 888 | 27 |
| 18 to 54 years | 530 | 19 |
| 55 years and older | 9 | 1 |
| Total | 2,008 | 66 |
Table 5. Confirmed measles cases by severe outcomes and year
| Severe outcome | 2025 | 2026 |
|---|---|---|
| Cases | 2,008 | 66 |
| Hospitalizations | 164 | 5 |
| ICU Admissions | 16 | 1 |
| Death | 1 | 0 |
- Counts are cumulative and not limited to those currently in hospital or ICU
- ICU admissions are included in the total count of hospitalizations
- Hospitalizations, ICU admissions and deaths are only included if the outcome was related to their measles infection.
Table 6. Confirmed measles cases by immunization status and year
| Immunization status1 | 2025 | 2026 |
|---|---|---|
| Unimmunized | 1,804 | 59 |
| 1 dose | 53 | 0 |
| 2 or more doses | 78 | 1 |
| Unknown | 73 | 6 |
| Total | 2,008 | 66 |
1Information on who is considered protected can be found in the Prevention of measles section.
Notes for Figure 2a-f:
- Excludes measles immunoglobulin administered as post-exposure prophylaxis
- Includes null doses administered to children < 12 months of age